Document is current

Article History

Received: 31 January 2022

Accepted: 16 November 2022

First Online: 31 December 2022

Declarations

:

: Institutional review board approval for the primary study, SWOG S1204, was provided by the Protocol Review Committee of the Cancer Therapy Evaluation Program on August 5, 2013.

: Informed consent was obtained from all participants in SWOG S1204.

: Not applicable.

: Jessica P. Hwang reports research funding to her institution from Merck. Rashmi Chugh reports research funding to her institution from AADI, Advenchen, Novartis, Epizyme, Lilly, Medivation, Mundipahrma, Glaxo Smith Kline, Janssen, Pfizer, Plexxikonn, Springworks, Qilu Puget Sound, and AstraZeneca. Rohit Loomba reports research funding to his institution from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes, and Terns Pharmaceuticals; reports consulting roles at Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals, and Viking Therapeutics; and is co-founder of LipoNexus. Scott D. Ramsey reports research funding to his institution from Bayer, Bristol-Myers Squibb, and Microsoft Corp and consulting roles at Bayer, Bristol-Myers Squibb, AstraZeneca, Merck, GRAIL, Pfizer, Seattle Genetics, Biovica, and Genentech. All other authors declare no competing interests.